Does Medicaid Cover Weight Loss Shots? A 2026 State-by-State Guide

Key Takeaways

• About 13 to 14 state Medicaid programs cover GLP-1 weight loss medications (Wegovy or Zepbound) for the chronic weight management indication as of April 2026.
• Most other states cover GLP-1s only for type 2 diabetes (Ozempic, Mounjaro) or for sleep apnea (Zepbound, after the December 2024 FDA approval).
• Prior authorization is required in nearly every state, with criteria including BMI thresholds, documented weight-loss attempts, and provider supervision.
• Federal law allows but does not require state Medicaid programs to cover obesity medications, leaving the decision to each state.
• If your state Medicaid doesn't cover weight loss shots, options include Wegovy/Zepbound savings cards (require commercial insurance), patient assistance programs, or compounded semaglutide/tirzepatide.

Direct answer (40-60 words)

Some Medicaid programs cover weight loss shots, but most don't. About 13 to 14 state Medicaid programs cover Wegovy or Zepbound for chronic weight management as of April 2026, including California, Massachusetts, Pennsylvania, Michigan, and Virginia. Most states cover GLP-1s only for type 2 diabetes or sleep apnea, not weight loss.

Table of contents

1. The 30-second answer
2. The federal Medicaid framework for obesity drugs
3. States that cover weight loss shots through Medicaid (April 2026)
4. States that don't cover weight loss shots
5. What Medicaid does cover for GLP-1s in non-covering states
6. Prior authorization criteria across Medicaid plans
7. What to do if your state doesn't cover weight loss shots
8. Patient assistance programs and self-pay options
9. Compounded GLP-1s through state-licensed pharmacies
10. FAQ
11. Sources
12. Footer disclaimers

The federal Medicaid framework for obesity drugs

Medicaid is jointly funded by federal and state governments. Each state runs its own Medicaid program within federal rules. For prescription drugs, federal law lets states decide whether to cover certain categories, including weight loss medications.

The relevant federal language: under the Social Security Act (Section 1927(d)(2)), states "may exclude or otherwise restrict" coverage of agents used for "anorexia, weight loss, or weight gain." This permissive exclusion has been the legal basis for many states excluding GLP-1 weight loss drugs from Medicaid formularies.

In November 2024, CMS proposed a rule that would have required Medicaid (and Medicare) to cover anti-obesity medications, treating obesity as a chronic disease. The proposal was paused under the new administration in early 2025 and has not been finalized. Coverage remains state-by-state (CMS, 2024 proposed rule; KFF analysis 2025).

Three things matter for patients:

Thing 1: Federal law allows weight loss drug coverage but doesn't require it. States have full discretion.

Thing 2: Even non-covering states cover GLP-1s for diabetes and OSA. The exclusion is for "weight loss" indication, not for the medication itself.

Thing 3: State policies are evolving. A state that doesn't cover weight loss shots in 2026 may add coverage in 2027, and vice versa.

States that cover weight loss shots through Medicaid (April 2026)

The states with confirmed Medicaid coverage for at least one GLP-1 (Wegovy, Zepbound, or both) for chronic weight management:

State	GLP-1s covered for weight loss	Notable conditions
California	Wegovy, Zepbound	BMI 30+, MTM enrollment, PA required
Connecticut	Wegovy	BMI 30+ or 27+ with comorbidity, PA required
Delaware	Wegovy, Zepbound	BMI 30+, lifestyle counseling documentation
Kansas	Wegovy	BMI 30+ or 27+ with comorbidity, PA required
Massachusetts	Wegovy, Zepbound	BMI 30+, registered dietitian referral, PA
Michigan	Wegovy	BMI 30+ or 27+ with comorbidity, PA required
Minnesota	Wegovy	BMI 30+, PA required
New Hampshire	Wegovy	BMI 30+ or 27+ with comorbidity, PA required
Pennsylvania	Wegovy, Zepbound	BMI 30+, behavioral counseling, PA
Rhode Island	Wegovy	BMI 30+, PA required
Vermont	Wegovy	BMI 30+, PA required
Virginia	Wegovy, Zepbound	BMI 30+, PA required
Wisconsin	Wegovy	BMI 30+ or 27+ with comorbidity, PA

Coverage in these states is typically restricted to FDA-approved chronic weight management medications: Wegovy (semaglutide) and Zepbound (tirzepatide). Saxenda (liraglutide) is also covered in some states. Ozempic and Mounjaro are not covered for weight loss because their FDA-approved indications are different (type 2 diabetes for Ozempic and Mounjaro).

Even in covering states, formularies and PA criteria can change with each plan year. The list above reflects April 2026 coverage based on KFF and state Medicaid agency data. Always verify directly with your state Medicaid agency or managed care plan.

States that don't cover weight loss shots

The remaining 36 to 37 state Medicaid programs do not cover GLP-1s for chronic weight management as of April 2026. This includes most large states (Texas, Florida, New York, Illinois, Ohio, Georgia, North Carolina, Arizona, Washington, and others).

Some non-covering states have publicly indicated they're reviewing coverage decisions, particularly in light of the strong clinical evidence from SURMOUNT-1 (Jastreboff et al., NEJM 2022) and STEP 1 (Wilding et al., NEJM 2021). The financial impact is the central concern. Wegovy at full Medicaid net price is roughly $700 to $900 per patient per month, and large states could see hundreds of thousands of eligible enrollees if coverage opens.

Coverage decisions are typically announced before each calendar year. If your state announces new coverage starting January 1, 2027, the change would apply to existing Medicaid enrollees automatically.

What Medicaid does cover for GLP-1s in non-covering states

Even if your state doesn't cover weight loss shots, Medicaid likely covers GLP-1s for two other conditions:

Type 2 diabetes. All state Medicaid programs cover at least one GLP-1 for type 2 diabetes management. Coverage typically includes Ozempic (semaglutide) and Mounjaro (tirzepatide), with prior authorization. If you have type 2 diabetes plus obesity, the GLP-1 prescription would be for diabetes management, and the weight loss is a side effect.

Obstructive sleep apnea. After the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024, many state Medicaid programs added coverage for this indication. Coverage criteria typically include BMI 30+, AHI 15+, and concurrent or attempted PAP therapy.

If you have either condition, coverage paths exist that don't require your state to cover "weight loss." Talk to your provider about whether you qualify based on a co-existing diagnosis.

Prior authorization criteria across Medicaid plans

PA criteria vary by state, but the most common requirements:

Criterion 1: BMI threshold. Either BMI 30+ alone, or BMI 27+ with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, OSA, or cardiovascular disease).

Criterion 2: Documented weight loss attempts. Most plans want a 6 to 12 month history of unsuccessful diet and exercise efforts. Some require formal participation in a structured weight loss program.

Criterion 3: Behavioral or lifestyle counseling. Ongoing engagement with diet, exercise, or behavioral therapy. Some states require referral to a registered dietitian or formal Medical Therapy Management (MTM) program.

Criterion 4: Step therapy. A trial of cheaper alternatives first. Some states require trying generic phentermine or naltrexone-bupropion before approving GLP-1s.

Criterion 5: Provider type. Some states require the prescription come from a primary care provider or endocrinologist. Direct-to-patient telehealth platforms may not qualify in some states.

Criterion 6: Medication-specific requirements. PA for Wegovy may differ from PA for Zepbound within the same state. Plans often prefer one over the other based on rebate negotiations.

PA approval rates for Medicaid weight loss medications run 50 to 70% on first submission across covering states (state Medicaid annual reports, 2024-2025). Denials often relate to incomplete documentation, which is fixable with a resubmission.

What to do if your state doesn't cover weight loss shots

Five paths to consider:

Path 1: Coverage through a different indication. If you have type 2 diabetes, Ozempic or Mounjaro is likely covered. If you have moderate-to-severe OSA, Zepbound is likely covered. Talk to your provider about whether you qualify.

Path 2: Patient assistance programs. Both Novo Nordisk (NovoCare) and Eli Lilly run patient assistance programs that provide free or low-cost medication for income-eligible patients without coverage. Income limits typically run up to 400% of the federal poverty level.

Path 3: Manufacturer self-pay programs. Eli Lilly's LillyDirect sells single-dose Zepbound vials for self-pay at $349 (2.5 mg) or $499 (5 mg+) per month, no insurance involved. Novo Nordisk has indicated direct-to-patient self-pay options for Wegovy as well.

Path 4: Compounded GLP-1s through state-licensed pharmacies. Compounded semaglutide and tirzepatide from 503A or 503B pharmacies typically cost $179 to $329 per month, no insurance required.

Path 5: Lobby for coverage. State Medicaid policies can change. Patient advocacy through your state representatives, state Medicaid agency public comment periods, or organizations like the Obesity Action Coalition can influence policy.

Patient assistance programs and self-pay options

Novo Nordisk Patient Assistance Program (NovoCare PAP):

• Eligibility: household income at or below 400% FPL, U.S. resident, no prescription drug coverage that covers Wegovy.
• What it provides: free Wegovy for up to 12 months, renewable.
• Application: NovoCare website, provider signs medical necessity portion.

Lilly Cares Patient Assistance Program:

• Eligibility: household income criteria (varies), U.S. resident, lack of insurance coverage for Zepbound.
• What it provides: free Zepbound for eligible patients.
• Application: Lilly Cares Foundation.

LillyDirect (self-pay vials):

• Eligibility: active prescription, U.S. resident, willing to pay self-pay.
• Pricing: $349 (2.5 mg) or $499 (5 mg+) per month, single-dose vials.

Manufacturer savings cards:

• Wegovy: requires commercial insurance, not Medicaid-eligible.
• Zepbound: requires commercial insurance, not Medicaid-eligible.

The savings cards (which advertise $25/month pricing) don't apply to any government coverage including Medicaid. Federal anti-kickback rules prohibit drug manufacturers from offering copay assistance to patients on government healthcare programs.

Compounded GLP-1s through state-licensed pharmacies

Compounded semaglutide and tirzepatide are prepared by state-licensed 503A or 503B compounding pharmacies in response to individual prescriptions. They contain the same active ingredients as Wegovy/Ozempic and Zepbound/Mounjaro, but they are not FDA-approved and are not interchangeable with brand-name products.

Pricing (as of April 2026):

• FormBlends compounded semaglutide: $179 to $279 per month.
• FormBlends compounded tirzepatide: $179 to $329 per month.
• Other licensed compounding pharmacies: $150 to $499 per month.

When compounded makes sense:

• Your state Medicaid doesn't cover weight loss shots.
• You don't qualify for patient assistance programs.
• You want predictable monthly pricing without insurance paperwork.
• Brand-name self-pay prices are out of reach.

When brand-name medications make more sense:

• Your state Medicaid does cover Wegovy or Zepbound.
• You qualify for the manufacturer patient assistance program (free).
• You strongly prefer FDA-approved medications and can afford the cash or LillyDirect price.

A licensed clinician should help you weigh the trade-offs. Compounded medications have not undergone FDA review and are not interchangeable with brand-name products. Internal link: see why is my compounded semaglutide red for color guidance.

FAQ

Does Medicaid cover Wegovy for weight loss? About 13 to 14 state Medicaid programs cover Wegovy for chronic weight management as of April 2026, including California, Massachusetts, Pennsylvania, Michigan, and Virginia. Most other states don't cover Wegovy for weight loss. All state Medicaid programs cover at least one GLP-1 for type 2 diabetes.

Does Medicaid cover Zepbound for weight loss? A subset of the states that cover Wegovy also cover Zepbound for weight management (California, Delaware, Massachusetts, Pennsylvania, Virginia). After the December 2024 FDA approval for OSA, most states added Zepbound coverage for the OSA indication, regardless of weight management coverage status.

Does Medicaid cover Ozempic for weight loss? No. Ozempic is FDA-approved for type 2 diabetes, not weight loss. Medicaid covers Ozempic only for the diabetes indication. Patients using Ozempic off-label for weight loss are not covered by Medicaid in any state.

Does Medicaid cover Mounjaro for weight loss? No. Mounjaro is FDA-approved for type 2 diabetes. Medicaid covers Mounjaro only for the diabetes indication. The same medication (tirzepatide) for weight loss is sold as Zepbound, which has its own coverage rules.

Why don't most state Medicaid programs cover weight loss shots? Federal law allows but doesn't require Medicaid coverage of weight loss medications. States cite cost as the primary reason for non-coverage. A 2024 CMS proposed rule would have required Medicaid coverage of anti-obesity medications, but the proposal was paused in early 2025.

What if I have type 2 diabetes and obesity? Medicaid covers GLP-1s for diabetes management in every state. If you have type 2 diabetes, your provider can prescribe Ozempic or Mounjaro for diabetes management, and the weight loss is a side effect of the medication.

What if I have sleep apnea and obesity? Following the December 2024 FDA approval of Zepbound for moderate-to-severe OSA, many state Medicaid programs cover Zepbound for OSA. Coverage requires BMI 30+, AHI 15+, and concurrent or attempted PAP therapy.

Can I use the Wegovy or Zepbound savings card with Medicaid? No. Federal anti-kickback rules prohibit drug manufacturers from offering copay assistance to Medicaid, Medicare, TRICARE, or VA patients. The savings cards work only for patients with commercial insurance.

How do I check my state's Medicaid coverage for weight loss shots? Visit your state Medicaid agency's website and search the preferred drug list (PDL) for "Wegovy" or "Zepbound." You can also call your managed care plan's member services line, or ask your provider's office to verify coverage.

What's the cheapest path to weight loss medication if Medicaid won't cover it? For income-eligible patients, the manufacturer patient assistance programs (NovoCare PAP for Wegovy, Lilly Cares for Zepbound) provide free medication. For others, compounded semaglutide or tirzepatide through licensed pharmacies typically runs $179 to $329 per month.

Will Medicaid cover weight loss shots in my state someday? Possibly. State Medicaid policies are evolving. The number of covering states has grown from about 6 in 2022 to about 13 in 2026. Federal CMS guidance, drug pricing negotiations, and state budget considerations all influence the trajectory.

Is compounded semaglutide or tirzepatide safe? Compounded GLP-1s prepared by state-licensed 503A or 503B pharmacies under individual prescriptions follow USP standards for sterile compounding. They are not FDA-approved and have not undergone the same review as brand-name products. Patients should obtain compounded medications only from licensed pharmacies through licensed providers.

Sources

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
3. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
4. Cubanski J, et al. State Medicaid coverage of weight-loss medications. Kaiser Family Foundation Issue Brief, 2024.
5. KFF. Analysis of CMS proposed rule on Medicaid and Medicare coverage of anti-obesity medications. KFF Health Policy Brief, 2025.
6. Centers for Medicare & Medicaid Services. Notice of Proposed Rulemaking: Coverage of Anti-Obesity Medications under Medicaid and Medicare. Federal Register, 2024.
7. Social Security Act, Section 1927(d)(2). Medicaid Drug Rebate Program statutory framework.
8. U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. FDA News Release, December 2024.
9. U.S. Department of Health and Human Services Office of Inspector General. Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons. HHS OIG, 2014.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.